Aligos Therapeutics (ALGS) Stock Price, Quote, News & History | Benzinga

Comments

Aligos Therapeutics Inc (ALGS) Stock Price, Quote, News & History

ALGSNASDAQ

Trade with Public

Trade with Public

$6.91

-0.08-1.14%

At close: Feb 13, 4:00 PM EST

$7.00

0.091.30%

After Hours: 5:29 PM EST

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$7.01

Close

$6.91

Volume / Avg.

50.03K / 73.45K

Day Range

$6.91 - $7.71

52 Wk Range

3.76 - 26.38

Market Cap

$43.08M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

5.6%

Days to Cover

3.46

Recent Aligos Therapeutics Inc News

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

Erica Kollmann

Beam Therapeutics Begins Dosing in Phase I/II AATD Study

Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo base editing therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD).

Zacks

Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Shares of Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-79.16M

Investing Cash Flow (TTM)

-15.83M

Financing Cash Flow (TTM)

101.61M

Free Cash Flow (TTM)

-79.53M

Capital Expenditure (TTM)

-373.00K

Net Change in Cash (TTM)

6.62M

Analyst Trends and Forecast

1

Aug 25

1

Sep 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$47.99M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

23.40

PB Ratio (TTM)

0.60

Earnings Yield % (TTM)

-193.71%

Earnings Yield % (FWD)

-126.18%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$11.67

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$54.00K

Total Cash

$41.95M

Debt to Equity

0.08

Issuance of Debt (TTM)

-$54.00K

Repayment of Debt (TTM)

-$54.00K

Key Statistics

Open

$7.01

Close

$6.91

Volume / Avg.

50.03K / 73.45K

Day Range

$6.91 - $7.71

52 Wk Range

3.76 - 26.38

Market Cap

$43.08M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

5.6%

Days to Cover

3.46

About

Sector

Health Care

Industry

Biotechnology

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for no...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Aligos Therapeutics (ALGS) stock?

A

You can purchase shares of Aligos Therapeutics (NASDAQ:ALGS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Aligos Therapeutics (ALGS) competitors?

A

Other companies in Aligos Therapeutics’s space includes: Galecto Inc (NASDAQ:GLTO), Kezar Life Sciences Inc (NASDAQ:KZR), Estrella Immunopharma Inc (NASDAQ:ESLA), OS Therapies Inc (AMEX:OSTX) and Tevogen Bio Holdings Inc (NASDAQ:TVGN).

Q

What is the forecast, or price target, for Aligos Therapeutics (ALGS) stock?

A

Aligos Therapeutics has a consensus price target of $46.67.

Q

What is the current price for Aligos Therapeutics (ALGS)?

A

The stock price for Aligos Therapeutics (NASDAQ: ALGS) is $7 last updated February 13, 2026 at 5:29 PM EST.

Q

Does Aligos Therapeutics (ALGS) pay a dividend?

A

There are no upcoming dividends for Aligos Therapeutics.

Q

When is Aligos Therapeutics (NASDAQ:ALGS) reporting earnings?

A

Aligos Therapeutics does not have any upcoming earnings scheduled.

Q

Is Aligos Therapeutics (ALGS) going to split?

A

There is no upcoming split for Aligos Therapeutics.

Q

What sector and industry does Aligos Therapeutics (ALGS) operate in?

A

Aligos Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Kezar Life Sciences Inc

Estrella Immunopharma Inc

OSTX

Tevogen Bio Holdings Inc

ABVC BioPharma Inc

Lisata Therapeutics Inc

Fortress Biotech Inc